Filana surges 12% on EPS beat amid tight cash runway
Former Cassava Sciences rebrands, but clinical hold on epilepsy program and litigation payment raise sustainability concerns
Filana Therapeutics, formerly known as Cassava Sciences, saw its shares surge 12% in early Thursday trading despite posting a narrower-than-expected loss and revealing a significantly tightened cash position. The stock, which traded under the new ticker symbol FLNA for the first time Wednesday, jumped to $2.38 from $2.12 on better-than-anticipated fourth-quarter results.
The biotechnology company reported a net loss of $0.26 per share for the quarter, beating analyst estimates of $0.27. For the full year 2025, the company recorded a net loss of $91 million, or $1.88 per share, compared to a $24.3 million loss in 2024. The wider annual loss primarily reflects a $108.1 million gain from warrant liabilities recorded in 2024 that did not recur.
More concerning to analysts is the company's deteriorating cash position. Filana ended 2025 with $95.5 million in cash and equivalents, down from $128.6 million at the start of the year. Management projects cash will decline further to between $47 million and $50 million by June 30, 2026, with an estimated $14 million to $17 million in operational cash burn during the first half of 2026.
Adding to the financial pressure, the company disclosed a $31.25 million payment for an estimated loss contingency related to securities litigation recorded in 2025, which will further deplete resources.
The rebranded company faces a significant regulatory hurdle: its simufilam Tuberous Sclerosis Complex-related epilepsy program remains under a full FDA clinical hold initiated in December 2025. The agency has requested additional preclinical data and protocol modifications before the proof-of-concept study can proceed, pushing back the anticipated trial timeline.
Rick Barry, President and CEO of Filana Therapeutics, characterized the rebranding as "a new beginning" for the company, emphasizing its focus on developing medicines that modulate the filamin A protein for central nervous system disorders. The corporate name change reflects the company's strategic pivot away from Alzheimer's disease after simufilam failed to show benefit in Phase III trials.
Research and development expenses fell 62% to $26.6 million in 2025 from $69.6 million in the prior year, largely due to the discontinuation of the Alzheimer's program. Management indicated the planned TSC epilepsy program is expected to be less costly than the discontinued Alzheimer's efforts.
The stock's positive reaction to earnings, despite the fundamental challenges of a shrinking cash runway and halted clinical program, suggests speculative trading rather than assessment of operational progress. With shares trading well below the 52-week high of $4.98, Filana Therapeutics faces critical months ahead as it works to resolve the FDA clinical hold while managing an increasingly constrained financial position.